MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.34 0.87

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.95

Max

17.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

110M

64M

Pardavimai

12M

100M

P/E

Sektoriaus vid.

30.561

35.739

Pelno marža

63.508

Darbuotojai

127

EBITDA

111M

84M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+106.98% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-69M

1.1B

Ankstesnė atidarymo kaina

16.47

Ankstesnė uždarymo kaina

17.34

Naujienos nuotaikos

By Acuity

46%

54%

179 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-07 16:58; UTC

Uždarbis

BMW Trims 2025 View, Citing Weaker Performance in China

2025-10-07 23:43; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025-10-07 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025-10-07 23:19; UTC

Rinkos pokalbiai

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025-10-07 22:40; UTC

Rinkos pokalbiai

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025-10-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 20:44; UTC

Karštos akcijos

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025-10-07 19:42; UTC

Rinkos pokalbiai

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025-10-07 19:23; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025-10-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025-10-07 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025-10-07 15:33; UTC

Rinkos pokalbiai

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025-10-07 15:25; UTC

Rinkos pokalbiai

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025-10-07 15:15; UTC

Rinkos pokalbiai

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025-10-07 15:04; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-10-07 15:04; UTC

Rinkos pokalbiai

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025-10-07 14:52; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

106.98% į viršų

12 mėnesių prognozė

Vidutinis 35.6 USD  106.98%

Aukščiausias 55 USD

Žemiausias 17 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

4

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

179 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat